PL2097453T3 - Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II) - Google Patents

Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II)

Info

Publication number
PL2097453T3
PL2097453T3 PL07848842T PL07848842T PL2097453T3 PL 2097453 T3 PL2097453 T3 PL 2097453T3 PL 07848842 T PL07848842 T PL 07848842T PL 07848842 T PL07848842 T PL 07848842T PL 2097453 T3 PL2097453 T3 PL 2097453T3
Authority
PL
Poland
Prior art keywords
amhr
receptor
monoclonal antibodies
human anti
antibodies against
Prior art date
Application number
PL07848842T
Other languages
English (en)
Inventor
Isabelle Teulon
André Pelegrin
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of PL2097453T3 publication Critical patent/PL2097453T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07848842T 2006-11-02 2007-10-31 Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II) PL2097453T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06291703A EP1918304A1 (en) 2006-11-02 2006-11-02 Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II)
PCT/IB2007/003301 WO2008053330A2 (en) 2006-11-02 2007-10-31 Monoclonal antibodies against the human anti-mullerian hormone type ii receptor (amhr-ii)
EP07848842A EP2097453B1 (en) 2006-11-02 2007-10-31 Monoclonal antibodies against the human anti-müllerian hormone type ii receptor (amhr-ii)

Publications (1)

Publication Number Publication Date
PL2097453T3 true PL2097453T3 (pl) 2011-09-30

Family

ID=37763855

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07848842T PL2097453T3 (pl) 2006-11-02 2007-10-31 Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II)

Country Status (12)

Country Link
US (2) US8278423B2 (pl)
EP (2) EP1918304A1 (pl)
JP (3) JP2010508810A (pl)
KR (2) KR20150036812A (pl)
CN (2) CN101573382B (pl)
AT (1) ATE502052T1 (pl)
CA (1) CA2667970C (pl)
DE (1) DE602007013282D1 (pl)
DK (1) DK2097453T3 (pl)
ES (1) ES2363732T3 (pl)
PL (1) PL2097453T3 (pl)
WO (1) WO2008053330A2 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1918304A1 (en) * 2006-11-02 2008-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II)
JP5565723B2 (ja) * 2009-04-07 2014-08-06 学校法人北里研究所 抗dcdモノクローナル抗体
WO2011045202A1 (en) * 2009-10-12 2011-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Selective antagonist or agonist of amhrii for modulating fertility
FR2959994B1 (fr) * 2010-05-12 2012-08-24 Lfb Biotechnologies Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii
CA2837472A1 (en) * 2011-05-27 2012-12-06 Fox Chase Cancer Center Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies
FR2984750B1 (fr) 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
ITRM20130455A1 (it) * 2013-08-05 2015-02-06 Alfonso Baldi Ligandi dell'ormone anti-mulleriano
CN104865391B (zh) * 2015-05-06 2016-06-22 薛金锋 人抗苗勒激素的酶联免疫检测试剂
EP3331569A1 (en) * 2015-08-07 2018-06-13 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
WO2017040969A1 (en) * 2015-09-02 2017-03-09 The Cleveland Clinic Foundation Ovarian cancer vaccines
US10851159B2 (en) * 2016-06-02 2020-12-01 Bloom Diagnostics Ag Antibodies that bind to human anti-Müllerian hormone (AMH) and their uses
EP3490611A4 (en) * 2016-07-26 2020-04-15 Trustees Of Tufts College ANTIBODY-CONJUGATED NANOPARTICLES AND MEDICAL USES THEREOF
FR3060394B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-amhrii
MX2019012136A (es) 2017-04-14 2020-07-20 Gamamabs Pharma Compuestos de union al receptor de la hormona antimulleriana tipo ii (amhrii) para prevenir o tratar canceres de pulmon.
CA3058282A1 (en) * 2017-04-14 2018-10-18 Gamamabs Pharma Amhrii-binding compounds for preventing or treating cancers
CN110531077B (zh) * 2018-05-25 2023-07-07 荣昌生物制药(烟台)股份有限公司 间皮素免疫组化检测试剂盒
US12331110B2 (en) 2018-09-05 2025-06-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against endotrophin and the use thereof
WO2020186158A2 (en) * 2019-03-13 2020-09-17 Ulmert Hans David Staffan Prame binding molecules and uses thereof
EP3789401A1 (en) 2019-09-03 2021-03-10 Gamamabs Pharma Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers
CN114450304B (zh) * 2019-09-27 2023-12-12 国家医疗保健研究所 抗苗勒管抑制物质抗体及其用途
EP3812008A1 (en) * 2019-10-23 2021-04-28 Gamamabs Pharma Amh-competitive antagonist antibody
WO2021155295A1 (en) 2020-01-31 2021-08-05 The Cleveland Clinic Foundation Anti-müllerian hormone receptor 2 antibodies and methods of use
CN112251444B (zh) * 2020-10-21 2023-05-16 恺佧生物科技(上海)有限公司 一种改造的amh基因序列及利用其制备amh的方法
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
CN113238057B (zh) * 2021-04-23 2022-10-14 迪瑞医疗科技股份有限公司 苗勒氏管抑制物受体化学发光免疫检测试剂盒及其制备方法
JP2024535644A (ja) * 2021-10-08 2024-09-30 ラノバ メディシンズ デベロップメント カンパニー, リミテッド 抗amhrii抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
EP1384487A4 (en) * 2001-03-29 2007-07-11 Kyowa Hakko Kogyo Kk MEDICINAL PRODUCT WITH A GENETICALLY MODIFIED ANTIBODY AGAINST GANGLIOSID GD3
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
WO2005005615A2 (en) * 2003-07-08 2005-01-20 Fox Chase Cancer Center Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer
EP1918304A1 (en) * 2006-11-02 2008-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II)
JP2013212800A (ja) * 2012-04-03 2013-10-17 Webasto Japan Kk サンルーフのウエザーストリップ構造及びウエザーストリップの取付方法

Also Published As

Publication number Publication date
WO2008053330A3 (en) 2008-10-23
WO2008053330A2 (en) 2008-05-08
JP5903717B2 (ja) 2016-04-13
JP2016102109A (ja) 2016-06-02
US8278423B2 (en) 2012-10-02
US9458239B2 (en) 2016-10-04
KR20090101897A (ko) 2009-09-29
CN101573382B (zh) 2013-08-21
DE602007013282D1 (de) 2011-04-28
CA2667970A1 (en) 2008-05-08
EP1918304A1 (en) 2008-05-07
ES2363732T3 (es) 2011-08-12
US20100135996A1 (en) 2010-06-03
CA2667970C (en) 2016-10-04
DK2097453T3 (da) 2011-06-27
EP2097453B1 (en) 2011-03-16
CN103396491A (zh) 2013-11-20
JP2014076992A (ja) 2014-05-01
EP2097453A2 (en) 2009-09-09
JP2010508810A (ja) 2010-03-25
ATE502052T1 (de) 2011-04-15
KR101686000B1 (ko) 2016-12-14
KR20150036812A (ko) 2015-04-07
CN101573382A (zh) 2009-11-04
US20130164300A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
DK2097453T3 (da) Monoklonale antistoffer mod humant Anti-Müllerian Hormon type II receptor (AMHR-II)
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
DE602006013029D1 (de) Anti-egfr-antikörper
NO20074563L (no) Novel anti-plgf antibody
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
IL258880A (en) Diarylhydantoin compounds
LT3656793T (lt) Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
NO20074474L (no) Antistoffer som binder til EPHA2 og fremgangsmate for anvendelse derav
NO20084546L (no) Diagnostikk og behandlinger for tumorer
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
MX2009002711A (es) Anticuerpos anti-receptor de folato alfa humanos y fragmentos de anticuerpo para la radioinmunoterapia de carcinoma de ovario.
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
NI200900115A (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano.
MA32288B1 (fr) Nouveaux anticorps utiles pour le traitement du cancer
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
UA106529C2 (uk) Гуманізоване антитіло до cxcr4 для лікування раку
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
WO2006084092A3 (en) Antibodies to oncostatin m receptor
CY1118918T1 (el) Παραγοντες εξαλειψης κυτταρων β, οπως αντισωματα enanti-cd20 ή θραυσματα αυτων για την αντιμετωπιση συνδρομου χρονιας κοπωσης
WO2014205342A3 (en) Methods for treatment of ovarian cancer
TR200902344T1 (tr) Anti-epidermal büyüme faktörü reseptör antikorları ile terapinin etkisinin geliştirilmesi için terapötik bileşimler.